Non-communicable diseases, particularly cancers such as lung, liver, and breast cancer, account for 77% of all deaths in Vietnam. This stark statistic underscores the urgent need for effective and affordable cancer treatments, a key point raised by healthcare professionals at the Sandoz Specialty Summit 2024.
Held on December 7, the summit was organized simultaneously in Ho Chi Minh City and Hanoi, gathering over 500 healthcare experts. The event focused on innovative therapies and real-world data aimed at addressing the growing healthcare challenges posed by cancer and osteoporosis in Vietnam.
Innovative Cancer Treatments Highlighted
One of the summit’s key discussions revolved around the use of Rituximab biosimilar in treating non-Hodgkin lymphoma. The biosimilar was praised for its proven efficacy in clinical studies and its cost-effectiveness, providing greater access to biological therapies for patients with RA-ILD (rheumatoid arthritis-associated interstitial lung disease). The Rituximab biosimilar was also featured in presentations based on insights from major international medical conferences, including ASH 2024 and EHA 2024.
Another major topic was Gefitinib Sandoz, a promising therapy for non-small cell lung cancer. Lung cancer is the second most common and difficult-to-treat cancer in Vietnam, making accessible treatments like Gefitinib crucial for improving patient outcomes.
Osteoporosis Care and Solutions
In addition to oncology, osteoporosis was a significant focus of the summit. Vietnam’s rapidly aging population is facing an increasing prevalence of osteoporosis, particularly among the elderly, who are at heightened risk of fractures. The summit spotlighted the use of acid zoledronic as a key solution for osteoporosis management. This treatment not only aids in reducing fractures and re-fractures but also enhances patient quality of life by improving compliance and offering cost-effective alternatives.
Commitment to Public Health
Charaf Eddine Kadri, General Director of Sandoz Vietnam, emphasized the company’s commitment to addressing Vietnam’s cancer and osteoporosis burdens. “With the growing cancer burden in Vietnam, we are committed to supporting healthcare professionals with innovative oncology therapies like Rituximab biosimilar to improve patient outcomes. Similarly, treatments like acid zoledronic represent a significant step forward in managing osteoporosis. By focusing on treatment effectiveness and patient compliance, we can make a profound impact on public health,” Kadri stated. He added that events like the Sandoz Specialty Summit serve as crucial platforms for sharing insights and fostering innovation in healthcare.
The summit underscored the importance of accessible and effective treatments for non-communicable diseases, particularly as Vietnam faces a demographic shift towards an older population. Through collaborative efforts, healthcare professionals aim to improve patient outcomes and reduce the burden of cancer and osteoporosis in the country.
Related Topics
Promising COPD Treatment: Vitamin B3 Shows Potential in Reducing Lung Inflammation
Why Kiwis Are Superior to Vitamin C Supplements for Immune Health, According to Experts
Vitamin D Supplements Show Promise in Lowering Blood Pressure in Older Adults With Obesity
